Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $26.22, for a total value of $393,300.00. Following the completion of the sale, the chief marketing officer directly owned 15,000 shares of the company’s stock, valued at approximately $393,300. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, April 1st, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.46, for a total value of $441,900.00.
• On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $49.10, for a total value of $736,500.00.
• On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $50.45, for a total value of $1,513,500.00.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock traded down $1.06 on Monday, reaching $24.50. 596,266 shares of the stock were exchanged, compared to its average volume of 727,496. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a twelve month low of $9.15 and a twelve month high of $53.65. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -9.68 and a beta of 2.50. The business has a 50 day moving average price of $33.41 and a two-hundred day moving average price of $37.97.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Analysts anticipate that Maze Therapeutics, Inc. will post -2.63 earnings per share for the current fiscal year.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. increased its stake in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the fourth quarter worth about $43,000. Finally, Russell Investments Group Ltd. increased its position in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter.

Wall Street Analysts Forecast Growth

MAZE has been the subject of a number of research reports. Truist Financial decreased their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Guggenheim lifted their price target on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Wedbush lifted their price target on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.